缬沙坦联合丹参多酚酸盐治疗高血压肾病对血压及肾功能的影响

Effect of valsartan and salvianolate on pressure and renal function in the treatment of hypertensive nephropathy

目的探讨缬沙坦联合丹参多酚酸盐治疗高血压肾病对血压及肾功能的影响。方法选取2015年7月至2016年7月我院收治的80例高血压肾病患者,随机分为观察组和对照组,每组40例。观察组患者采取缬沙坦联合丹参多酚酸盐治疗,对照组患者单用缬沙坦治疗,对比两组患者的临床疗效,以及治疗前后的血压、晨尿蛋白/尿肌酐、SCr及Cys-C等指标水平。结果观察组患者治疗总有效率(92.50%)明显高于对照组(70.00%)(P<0.05)。治疗前,两组患者的血压、SCr、Cys-C、晨尿蛋白/尿肌酐比较,差异无统计学意义(P>0.05);治疗后,观察组患者的血压、SCr、Cys-C、晨尿蛋白/尿肌酐均明显下降,与治疗前和对照组治疗后比较,差异具有统计学意义(P<0.05)。结论缬沙坦联合丹参多酚酸盐治疗高血压肾病具有显著疗效,能明显减轻患者临床症状,且对患者肾功能具有保护作用,可在临床推广。

Objective To study the effect of valsartan and salvianolate on pressure and renal function in the treatment of hypertensive nephropathy. Methods A total of 80 cases of patients with hypertensive nephropathy admitted into our hospital from July 2015 to July 2016 were randomly divided into control group and observation group, with 40 cases in each group. Patients in the observation group were given valsartan and salvianolate, while patients in the control group were given valsartan alone. The clinical effects, and the levels of pressure, urinary protein, SCr and Cys-C before and after treatment of the two groups were compared. Results The total effective rate of the observation group （92.50%） was higher than 70.00% of the control group （P〈0.05）. Before treatment, the levels of blood pressure, SCr, Cys-C and morning urine protein/creatinine of the two groups were not statistically significant （P〉0.05）; after treatment, the levels of blood pressure, SCr, Cys-C and morning urine protein/creatinine of the observation group were significantly decreased, and the differences were statistically significant compared with those before treatment and the control group after treatment （P〈0.05）. Conclusion Application of valsartan and salvianolate in the treatment of hypertensive nephropathy has significant clinical efficacy, it can relief patients clinical symptom and protect the renal function, which can be considered to be promoted in clinic.